Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma

This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma.

THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Inclusion Criteria:

• Allergic asthma patients
• Inadequately controlled patients

Exclusion Criteria:

• - History of severe anaphylactoid or anaphylactic reactions
• Previous treatment with omalizumab
• History of cancer or cancer

Other protocol-defined exclusion criteria may apply.